ゾフルーザ顆粒 2%分包

第 2 部 (モジュール 2) : CTD の概要 (サマリー)

2.7 臨床概要

2.7.5 参考文献

塩野義製薬株式会社

目次

2.7.5 参考文献 3

2.7.5 参考文献

<2.7.1 生物製剤宅試験及び関連する分析法>

該当なし.

<2.7.2 臨床薬理試験>

1. Anderson BJ, Holford NH. Tips and traps analyzing pediatric PK data. Paediatr Anaesth 2011; 21 (3): 222-37.
2. World Health Organization. Laboratory methodologies for testing the antiviral susceptibility of influenza viruses: neuraminidase inihibitor (NAI). 2023. https://www.who.int/teams/global-influenza-programme/laboratory-network/quality-assurance/antiviral-susceptibility-influenza/neuraminidase-inhibitor. Accessed on 4 Apr 2025.
3. Ishiguro N, Koseki N, Kaiho M, et al. Clinical effectiveness of four neuraminidase inhibitors (oseltamivir, zanamivir, laninamivir, and peramivir) for children with influenza A and B in the 2014-2015 to 2016-2017 influenza seasons in Japan. J Infect Chemother. 2018;24(6):449-57.
4. Gubareva LV, Mishin VP, Patel MC, et al. Assessing baloxavir susceptibility of influenza viruses circulating in the United States during the 2016/17 and 2017/18 seasons. Euro Surveill 2019;24 (3).
5. 国立感染症研究所．抗インフルエンザ薬耐性株サーベイランス．2025 年 7 月 2 日．https://id-info.jihs.go.jp/surveillance/idss/inful/report/2025/0702/index.html. Accessed on 23 Jul 2025.
6. World Health Organization. Recommended composition of influenza virus vaccines for use in the 2020 southern hemisphere influenza season. https://cdn.who.int/media/docs/default-source/influenza/who-influenza-recommendations/vcm-southern-hemisphere-recommendation-2020/201909-recommendation.pdf?sfvrsn=f34905d9_13&download=true. Accessed on 4 Apr 2025.
7. World Health Organization. Recommended composition of influenza virus vaccines for use in the 2020- 2021 northern hemisphere influenza season. https://cdn.who.int/media/docs/default-source/influenza/who-influenza-recommendations/vcm-northern-hemisphere-recommendation-2020-2021/202002-recommendation.pdf?sfvrsn=6868e7b3_21&download=true. Accessed on 4 Apr 2025.
8. World Health Organization. Recommended composition of influenza virus vaccines for use in the 2021 southern hemisphere influenza season. https://cdn.who.int/media/docs/default-source/emergency-preparedness/global-influenza-programme/recommended-composition-of-influenza-virus-vaccines/202009-recommendation.pdf?sfvrsn=1331fa94_2&download=true. Accessed on 4 Apr 2025.
9. World Health Organization. Recommended composition of influenza virus vaccines for use in the 2021- 2022 northern hemisphere influenza season. https://cdn.who.int/media/docs/default-source/influenza/who-influenza-recommendations/vcm-northern-hemisphere-recommendation-2021-2022/202102_recommendation.pdf?sfvrsn=2af603d8_12&download=true. Accessed on 4 Apr 2025.
10. World Health Organization. Recommended composition of influenza virus vaccines for use in the 2022 southern hemisphere influenza season. https://cdn.who.int/media/docs/default-source/influenza/who-influenza-recommendations/vcm-southern-hemisphere-recommendation-2022/202109_recommendation.pdf?sfvrsn=698a54b9_12&download=true. Accessed on 4 Apr 2025.

11. World Health Organization. Recommended composition of influenza virus vaccines for use in the 2022- 2023 northern hemisphere influenza season. https://cdn.who.int/media/docs/default-source/influenza/who-influenza-recommendations/vcm-northern-hemisphere-recommendation-2022-2023/202202_recommendation.pdf?sfvrsn=5c88e006_13&download=true. Accessed on 4 Apr 2025.
12. World Health Organization. Recommended composition of influenza virus vaccines for use in the 2023 southern hemisphere influenza season. https://cdn.who.int/media/docs/default-source/influenza/who-influenza-recommendations/vcm-southern-hemisphere-recommendation-2023/202209_recommendation.pdf?sfvrsn=83a26d50_3&download=true. Accessed on 4 Apr 2025.
13. World Health Organization. Recommended composition of influenza virus vaccines for use in the 2023- 2024 northern hemisphere influenza season. https://cdn.who.int/media/docs/default-source/influenza/who-influenza-recommendations/vcm-northern-hemisphere-recommendation-2023-2024/202302_seasonal_recommendation_a.pdf?sfvrsn=42612ae5_3&download=true. Accessed on 4 Apr 2025.
14. World Health Organization. Recommended composition of influenza virus vaccines for use in the 2024 southern hemisphere influenza season. https://cdn.who.int/media/docs/default-source/influenza/who-influenza-recommendations/vcm-southern-hemisphere-recommendation-2024/202309_recommendation.pdf?sfvrsn=2c2cbebd_8&download=true. Accessed on 4 Apr 2025.
15. World Health Organization. Recommended composition of influenza virus vaccines for use in the 2024-2025 northern hemisphere influenza season. https://cdn.who.int/media/docs/default-source/influenza/who-influenza-recommendations/vcm-northern-hemisphere-recommendation-2024-2025/recommended-composition-of-influenza-virus-vaccines-for-use-in-the-2024-2025-northern-hemisphere-influenza-season.pdf?sfvrsn=2e9d2194_7&download=true. Accessed on 4 Apr 2025.

<2.7.3 臨床的有効性>

1. Suzuki E, Ichihara K. The course of fever following influenza virus infection in children treated with oseltamivir. J Med Virol 2008; 80 (6): 1065-71.
2. Koseki N, Kaiho M, Kikuta H, et al. Comparison of the clinical effectiveness of zanamivir and laninamivir octanoate for children with influenza A(H3N2) and B in the 2011-2012 season. Influenza Other Respir Viruses 2014; 8 (2): 151-8.
3. Ishiguro N, Koseki N, Kaiho M, et al. Clinical effectiveness of four neuraminidase inhibitors (oseltamivir, zanamivir, laninamivir, and peramivir) for children with influenza A and B in the 2014-2015 to 2016-2017 influenza seasons in Japan. J Infect Chemother 2018; 24 (6): 449-57.

<2.7.4 臨床的安全性>

該当なし.